A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

References

• American Diabetes Association. Position statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl1);S62–9.
   PubMedGoogle Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977–86.
   PubMed Web of Science ®Google Scholar
• Stratton MI, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405–12.
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005;54:1615–25.
   PubMed Web of Science ®Google Scholar
• Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med. 1997;14 (Suppl 3):S25–31
   PubMedGoogle Scholar
• Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, . Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–31.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Position statement. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33 (Suppl1):S23.
   PubMedGoogle Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281;2005–12.
   PubMed Web of Science ®Google Scholar
• ; Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
   PubMed Web of Science ®Google Scholar
• Chao EC, Henry RR. SGLT2 inhibition: a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–9.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75: 1272–7.
   PubMed Web of Science ®Google Scholar
• Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin Am Soc Nephrol. 2010;5:133–41.
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulindependent diabetes. Diabetes. 2005;54:3427–34.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Devineni D, Rothenberg P. The renal glucose threshold is increased in patients with type 2 diabetes: results from a novel method for measuring the renal threshold. ADA 2010 meeting abstract 2186-PO.
   Google Scholar
• Ehrenkranz JRL, Lewis NG, Kahn CR, Ross J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987; 79:1510–5.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610–30.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. The Cochrane Collaboration; updated February 2008. Available at: http://www.cochrane-handbook.org (accessed 26 May 2009).
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62: 1006–12.
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–9.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656–62.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Woo V, Pahor A, Sugg J, Langkilde A, Parikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetologia. 2010;53(S1):S348–9.
   Google Scholar
• Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375: 2223–33.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Jimenez Ramos S, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217–24.
   PubMed Web of Science ®Google Scholar
• Strojek K, Hruba V, Elze M, Langkilde A, Parikh S. Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy. Diabetologia. 2010;53(S1):S347–8.
   Google Scholar
• Rosenstock J, Polidori D, Zhao Y, Sha S, Arbit D, Usiskin K, . Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin. Diabetologia. 2010; 53(S1):S349.
   Google Scholar
• Rothenberg PL, Devineni D, Ghosh A, Polidori AD, Hompesch M, Arnolds S, . Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes: Results of a phase 1b study. Diabetologia. 2010;53(S1):S350–1.
   Google Scholar
• Ferrannini E, Seman LI, Seewaldt-Becker E, Hantel S, Pannetti S, Woerle HJ. The potent and highly selective sodium-glucose co-cransporter (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(S1):S351.
   Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, . BI 10773, a Sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes ADA 2010 meeting abstract 629-P.
   Google Scholar
• Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, . Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Diabetes ADA 2010 meeting abstract 571-P.
   Google Scholar
• Freiman J, Ruff DA, Frazier KS, Combs K, Turnage A, Shadoan M, . LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28 days in patients with type 2 diabetes (T2DM). Diabetes ADA 2010 meeting abstract 17-LB.
   Google Scholar
• Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, . Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–6.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Sarich T, Devineni D, Rothenberg PL. Canagliflozin lowers the renal threshold for glucose excretion in lean, obese and type 2 diabetic subjects. Diabetologia. 2010;53(Suppl1):S350.
   Google Scholar
• Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, . Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, induces dose-dependent urinary glucose excretion in healthy subjects. Diabetes ADA 2010 meeting abstract 76-OR.
   Google Scholar
• Sarich T, Devineni D, Ghosh A, Wexler D, Shalayda K, Blake J, . Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects. Diabetes ADA 2010 meeting abstract 567–P.
   Google Scholar
• Macdonald FR, Peel JE, Jones HB, Mayers RM, Westgate L, Whaley JM, . The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12:1004–12.
   PubMed Web of Science ®Google Scholar
• Ueta K, Torres TP, Mccoy GL, Farmer TD, Condren AB, Whitfield T, . Normalization of hyperglycemia by inhibiting SGLT2 prevents progressive reduction of hepatic glucokinase (GK) expression and improves hepatic glucose metabolism (HGM) in Zucker diabetic fatty (ZDF) rats. Diabetes ADA 2010 meeting abstract 608–P.
   Google Scholar
• Bradford BJ, Allen MS. Phlorizin induces lipolysis and alters meal patterns in both early- and late-lactation dairy cows. J Dairy Sci. 2007;90:1810–5.
   PubMedGoogle Scholar
• Devenney J, Harvey S, Rooney S, Godonis H, Washburn W, Whaley J, . The effect of dapagliflozin, a highly selective SGLT2 inhibitor, on body weight in diet-induced obese rats. Presented at The Obesity Society Annual Scientific Meeting 2007; New Orleans, LA, 2007; Abstract 0384.
   Google Scholar
• Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510–6.
   PubMed Web of Science ®Google Scholar